Список литературы

1. Berruti A, Baudin E, Gelderblom H et al. Adrenal cancer: ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for diagnosis, treatment and follow-up on behalf of the ESMO Guidelines Working Group. Annals of Oncology. 2012; 23: 131 - 138.

2. NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine tumor, Version 1.2014.

3. Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005; 12: 667.

4. Langer P, Cupisti K, Bartsch DK et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg. 2002; 26: 891 - 896.

5. Gicquel C, Le Bouc Y. Molecular markers for malignancy in adrenocortical tumors. Horm Res. 1997; 47: 269 - 272.

6. Бельцевич ДГ, Кузнецов НС, Солдатова ТВ, Ванушко ВЭ. Инциденталома надпочечников. Эндокринная хирургия. 2009. N 1.

7. Funder JW (https://www.ncbi.nlm.nih.gov/pubmed/?term=Funder%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=18552288), Carey RM (https://www.ncbi.nlm.nih.gov/pubmed/?term=Carey%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=18552288) et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. (https://www.ncbi.nlm.nih.gov/pubmed/18552288) 2008; 93(9): 3266-81.

8. Guignat L (https://www.ncbi.nlm.nih.gov/pubmed/? term=Guignat%20L%5BAuthor%5D&cauthor=true&cauthor_uid=20375177), Bertherat J (https://www.ncbi.nlm.nih.gov/pubmed/? term=Bertherat%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20375177). The diagnosis of Cushing"s syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol. (https://www.ncbi.nlm.nih.gov/pubmed/20375177) 2010; 163(1): 9 - 13.

9. Lenders JW (https://www.ncbi.nlm.nih.gov/pubmed/? term=Lenders%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=24893135), Duh QY (https://www.ncbi.nlm.nih.gov/pubmed/?term=Duh%20QY%5BAuthor%5D&cauthor=true&cauthor_uid=24893135), Eisenhofer G (https://www.ncbi.nlm.nih.gov/pubmed/?term=Eisenhofer%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24893135) et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. и J Clin Endocrinol Metab. (https://www.ncbi.nlm.nih.gov/pubmed/24893135) 2014; 99(6): 1915-42.

10. Libe R, Dall'Asta C, Barbetta L et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002; 147: 489 - 494.

11. Terzolo M, Reimondo G, Bovio S, Angeli A Subclinical Cushing's syndrome. Pituitary. 2004; 7: 217 - 223.

10. Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps JL, C, Amar L, Rault A, Henry JF, Carnaille B. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012; 36(6): 1382 - 1388.

11. Li XG, Zhang DX, Li X. et al. Adrenocorticotropic hormone-producing pheochromocytoma: a case report and review of the literature. Chin Med J (Engl). 2012; 125(6): 1193 - 1196.

12. Cohade C, Broussaud S, Louiset E, Bennet A, Huyghe E, Caron P. Ectopic Cushing"s syndrome due to a pheochromocytoma: a new case in the postpartum and review of literature. Gynecol Endocrinol. 2009; 25(9): 624 - 627.

13. Gardet V et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens. 2001; 19: 1029 - 1035.

14. Nieman LK, Biller BMK, Findling JW et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline Journal of Clin Endoc & Met. 2008; 93(5): 1526 - 1540.

15. Newell-Price J, Trainer P, Besser M, Grossman A The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing"s states. Endocr Rev 1998; 19: 647 - 672.

16. Pecori Giraldi F, Ambrogio AG, De Martin Met al. Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007; 92: 4123 - 4129.

17. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2006; 29: 471 - 482.

18. Mitchell IC, Auchus RJ, Juneja K et al. "Subclinical Cushing's syndrome" is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007; 142: 900 - 905.

19. Mitchell IC, Auchus RJ, Juneja K et al. "Subclinical Cushing's syndrome" is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007; 142: 900 - 905.

20. Reincke M Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am. 2000; 29: 43 - 56.

21. Pacak K Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069 - 4079.

22. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol. 2003; 29: 483 - 490.

23. Young W.F., Jr. The Incidentally Discovered Adrenal Mass. N Engl J Med. 2007; 356: 601-10.

24. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin Endocrinol Metab. 2008; 93(9): 3266 - 3281.

25. Трошина ЕА, Бельцевич ДГ, Молашенко НВ. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клиническая медицина. 2009; 5: 15 - 20.

26. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85(2): 637 - 644. (http://www.ncbi.nlm.nih.gov/pubmed/10690869)

27. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997; 47: 279 - 283. (http://www.ncbi.nlm.nih.gov/pubmed/10690869)

28. Chang A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Chang%20A%5BAuthor%5D&cauthor=true&cauthor_uid=3823423) Glazer HS. Adrenal gland: MR imaging. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Glazer%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=3823423) Radiology. 1987; 163(1): 123-8. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

29. Metser U, Miller E, Lerman H et al. ¹⁸F-FDG PET/CT in the Evaluation of Adrenal Masses. J Nucl Med. 2006; 47(1): 32 - 37. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

30. M. Blake, P. Prakash, C.Cronin. PET/CT for Adrenal Assessment Am J Roentgenology. 2010; 195(2): 195. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

31. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006; 91: 2665. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

32. Leboulleux S, Dromain C, Bonniaud G et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006; 91: 920. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

33. Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer. 2011; 2: 354. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

34. Harisinghani MG, Maher MM, Hahn PF et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin Radiol. 2002; 57: 898 - 901. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

35. Arellano RS, Harisinghani MG, Gervais DA et al Imageguided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol. 2003; 32: 3 - 10. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

36. Welch TJ, Sheedy PF II, Stephens DH et al. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology. 1994; 193: 341 - 344. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

37. Casola G, Nicolet V, van Sonnenberg E et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology. 1986; 159: 733 - 735. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

38. McCorkell SJ, Niles NL. Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistake. Am J Roentgenol. 1985; 145: 113 - 114. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

39. Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007; 3: 92 - 102. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

40. Saeger W, Fassnacht M, Chita R. High Diagnostic Accuracy of Adrenal CoreBiopsy: Results of the German and Austrian Adrenal Network Multicenter Trial in 220 Consecutive Patients. Human pathology. 2003; 34(2): 180 - 186. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

41. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001; 25: 914 - 926 (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

42. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003; 169: 5 - 11. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

43. Miller BS, Gauger PG, Hammer GD et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010; 395: 955. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

44. Fassnacht M, Johanssen S, Quinkler M et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115: 243. (https://www.ncbi.nlm.nih.gov/pubmed/3823423)

45. Shen WT, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Shen%20WT%5BAuthor%5D&cauthor=true&cauthor_uid=15719374)Sturgeon C, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Sturgeon%20C%5BAuthor%5D&cauthor=true&cauthor_uid=15719374)Duh QY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Duh%20QY%5BAuthor%5D&cauthor=true&cauthor_uid=15719374)J Surg Oncol. 2005; 89(3): 186-92 (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

46. B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010; 17: 265. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

47. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006; 91: 2027. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

48. Филимонюк А.В., Харченко Н.В., Леонов Б.И., Смирнова Е.А., Антонов А.К., Смелкова Н.И. Непосредственные и отдаленные результаты хирургического лечения больных адренокортикальным раком. Вестник новых медицинских технологий (электронное издание). 2013; 1 [Электронный ресурс]. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

49. Reibetanz J, Jurowich C, Erdogan I et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012; 255: 363. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

50. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012 152(1): 123-32. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

51. Porpiglia F, Miller BS, Manfredi M et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011; 2: 372. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

52. Brix D, Allolio B, Fenske W et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010; 58: 609. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

53. Donatini G, Caiazzo R, Do Cao Ch et al. Long-Term Survival After Adrenalectomy for Stage I/II Adrenocortical Carcinoma (ACC): A Retrospective Comparative Cohort Study of Laparoscopic Versus Open Approach. Ann Surg Oncol. 2014; 21: 284 - 291. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

54. McCauley LR, Nguyen MM. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr Opin Urol. 2008; 18: 134. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

55. Gonzalez RJ, Shapiro S, Sarlis N et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery. 2005; 138(6): 1078. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

56. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012; 152: 1150 - 1157. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

57. Leboulleux S, Deandreis D, Ghuzlan A Al et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010; 162: 1147 - 1153 (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

58. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999; 6(8): 719 - 726. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

59. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992; 112(6): 972 - 979. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

60. Bellantone R, Ferrante A, Boscherini M, et al.: Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997, 122: 1212 - 1218. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

61. Porpiglia F, Fiori C, Scarpa RM et al. The role of surgery in the management of recurrent adrenocortical carcinoma: results of a retrospective study. Eur Urol Suppl. 2009; 8(4): 305. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

62. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984; 8(3): 163 - 169. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

63. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009; 40(6): 757 - 768. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

64. van Slooten H, Schaberg A, Smeenk D, Moolenar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985 Feb 15; 55(4): 766 - 773. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

65. Blanes A et al. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol. 2007; 127(3): 398 - 408. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

66. Филиппова О.В. Адренокортикальный рак: клинические проявления и морфологическая диагностика/Филиппова О.В., Хмельницкая Н.М.//Медицинский альманах. 2011; 5: 113 - 116. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

67. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005; 6: 386 - 394. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

68. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 2000; 33: 1197 - 1200. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

69. Dickstein G. Is there a role of low dose of mitotane as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab. 1999; 84: 1488 - 1489. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

70. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993; 71: 3119 - 3123. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

71. Terzolo M, Angeli A, Fassnacht M Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007; 356(23): 2372. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

72. Clinical trials gov. identifier NCT00777244, start 2008, update 2013. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

73. Lubitz JA, Freeman L, Okun R Mitotane use in inoperable adrenalcortical carcinoma. JAMA. 1973; 223: 1109 - 1112. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

74. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p_-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984; 20: 47 - 53. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

75. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994; 69: 947 - 951. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

76. Baudin E, Pellegriti G, Bonnay M et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001; 92: 1385 - 1392. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

77. Heilmann P, Wagner P, Nawroth PP, Ziegler R [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p_-DDD blood levels]. Med Klin. 2001; 96: 371 - 377. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

78. Becker D, Schumacher OP. o,p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med. 1975; 82: 677 - 679. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

79. Boven E, Vermorken JB, van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with o,p_-DDD. Case report and literature review. Cancer. 1984; 53: 26 - 29. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

80. Krzisnik C, Petric G, Jereb B. Complete response of metastatic adrenal cortical carcinoma to o,p_-DDD in a child. Pediatr Hematol Oncol. 1988; 5: 65 - 69. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

81. Lim MC, Tan YO, Chong PY, Cheah JS. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Ann Acad Med Singapore. 1990. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

82. Decker RA, Kuehner ME. Adrenocortical carcinoma. Am Surg. 1991; 57: 502 - 513. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

83. Remond S, Bardet S, Charbonnel B. Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP-DDD alone. Presse Med. 1992; 21: 865. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

84. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest. 2001; 24: 532 - 535. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

85. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004; 60: 273 - 287. 19: 540544. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

86. Fassnacht M, R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician"s update. Nat Rev Endocrinol. 2011; 7: 323. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

87. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf). 1989; 31: 51 - 57. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

88. Cordon-Cardo C, O"Brien JP, Boccia J et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38: 1277 - 1287. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

89. Flynn SD, Murren JR, Kirby WM et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992; 112: 981 - 986. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

90. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81: 116 - 124. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

91. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Anticancer Res. 1994; 14: 1009 - 1016. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

92. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer. 1993; 29A: 1036 - 1038. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

93. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study GroupN Engl J Med. 2012; 366(23): 2189. (https://www.ncbi.nlm.nih.gov/pubmed/15719374)

94. Sperone P, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Sperone%20P%5BAuthor%5D&cauthor=true&cauthor_uid=20410174) Ferrero A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ferrero%20A%5BAuthor%5D&cauthor=true&cauthor_uid=20410174) Daffara F et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Daffara%20F%5BAuthor%5D&cauthor=true&cauthor_uid=20410174)Endocr Relat Cancer. 2010; 17(2): 445-53 (https://www.ncbi.nlm.nih.gov/pubmed/20410174)

95. Martin Fassnacht, Matthias Kroiss, and Bruno Allolio. Update in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2013, 98(12): 4551 - 4564. (https://www.ncbi.nlm.nih.gov/pubmed/20410174)

96. Le Tourneau C, Hoimes C. J., Zarwan C. et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity. J Clin Oncol 34, 2016 (suppl; abstr 4516) (https://www.ncbi.nlm.nih.gov/pubmed/20410174)

97. Polat B, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Polat%20B%5BAuthor%5D&cauthor=true&cauthor_uid=19402169) Fassnacht M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Fassnacht%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19402169) Pfreundner L. Radiotherapy in adrenocortical carcinoma. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Pfreundner%20L%5BAuthor%5D&cauthor=true&cauthor_uid=19402169)Cancer. 2009; 115(13): 2816-23 (https://www.ncbi.nlm.nih.gov/pubmed/19402169)

98. Sabolch A, Feng M, Griffith K et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011; 80: 1477 - 1484. Habra MA, Ejaz S, Feng L et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013; 98: 192 - 197 (https://www.ncbi.nlm.nih.gov/pubmed/19402169)

99. Icard P, Goudet P, Charpenay C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg. 2001; 25: 891 - 897. (https://www.ncbi.nlm.nih.gov/pubmed/19402169)

100. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996; 119: 161 - 170. (https://www.ncbi.nlm.nih.gov/pubmed/19402169)

101. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963 - 970; discussion, 970 - 971. (https://www.ncbi.nlm.nih.gov/pubmed/19402169)

102. Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970 - 1984. World J Surg. 1992; 16: 663 - 667; discussion, 668. (https://www.ncbi.nlm.nih.gov/pubmed/19402169)

103. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001; 92: 1113 - 1121. (https://www.ncbi.nlm.nih.gov/pubmed/19402169)